Autopsy report · NCT00762684

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

“Hepatic safety signal identified.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 10 months after it had already started.
• Ran for about 1 month before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Takeda

Sponsor type

Industry

Conditions

Diabetes Mellitus

Interventions

TAK-559; Placebo

Participants

8

Trials that died the same way

• Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
  “Due to potential concerns about liver safety (See Detailed Description)” (65% match in meaning)
• A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
  “safety issue observed on another hepatocellular study using OSI906” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.